Medivir and county councils conclude agreement on Olysio®-based treatment for hepatitis C

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company has
entered into an agreement with Swedish county councils regarding the treatment
of hepatitis C with Olysio® (simeprevir).

The Dental and Pharmaceutical Benefits Agency (TLV) has concluded that treatment
with Olysio® (simeprevir) is beneficial from a health economics viewpoint in the
treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of
previous treatment.

A risk-sharing agreement between Medivir and the Swedish county councils has
been drawn up in parallel with TLV’s health economic evaluation. The agreement
offers the county councils and Medivir an increased degree of predictability
with regard to treatment costs and the use of Olysio®, in that the risk-sharing
applies both in relation to treatment results and to the number of patients who
will be treated.

“Treatment with Olysio® has already helped to cure a large number of people from
hepatitis C, both in Sweden and globally. I believe that the agreement will help
to ensure equal treatment across all of Sweden’s county councils and that more
hepatitis C patients will get the opportunity to become cured through treatment
with Olysio® , wherever they live,” says Henrik Krook, EVP Commercial at
Medivir.

Joint county council recommendations related to the use of Olysio® will be
designed by the New Pharmaceutical Product Therapies (NLT) group (a group within
the Swedish Association of Local Authorities and Regions tasked with evaluating
new pharmaceutical products and therapies). The NLT group will have a meeting
October the 30th regarding a protocol for structured introduction of Olysio®.

For more information, please contact:
Henrik Krook, EVP Commercial, mobile: +46 705 616 999
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Swedish Securities Market Act to make the
information in this press release public. The information was submitted for
publication at 08.30 CET on 30 October 2014.

About Simeprevir (Olysio®)
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D
Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C
infection as a component of a combination antiviral treatment regimen.
Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4
infected patients with compensated liver disease, including cirrhosis. Janssen
is responsible for the global clinical development of simeprevir and has
exclusive, worldwide marketing rights, except in the Nordic countries.
Medivir AB retains marketing rights for simeprevir in these countries under the
marketing authorisation held by Janssen‐Cilag International NV. Simeprevir was
approved for the treatment of chronic hepatitis C infection as part of an
antiviral treatment regimen in combination with pegylated interferon and
ribavirin in genotype 1 infected adults with compensated liver disease,
including cirrhosis. Simeprevir was approved in September 2013 in Japan, in
November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014
in Mexico and Australia.

In May 2014, simeprevir was granted marketing authorisation by the European
Commission (EC) for the treatment of adult patients with genotype 1 or genotype
4 chronic HCV. Following the EMA approval, it has so far been made available in
several EU countries in conjunction with reimbursement. Simeprevir (Olysio) is
marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada
and Olysio® in the U.S. and European Union.

About Medivir
Medivir is an emerging and profitable research‐based pharmaceutical company with
an established marketing and sales organisation in the Nordic region with a
broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the
hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio
in the Nordic region are generated through the company’s own sales and marketing
organisation. Medivir’s research and development portfolio of pharmaceuticals is
based on the company’s expertise within protease inhibitor design and
nucleoside/nucleotide science. The company’s research and development focus is
within infectious diseases and oncology and the on-going clinical projects in
osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.